Two Phase 1 studies assessed effects of ABT-450 ( 150 mg coadministered with ritonavir 100 mg once daily ) , ombitasvir ( 25 mg once daily ) , and dasabuvir ( 400 mg twice daily ) on the pharmacokinetics , safety , and tolerability of a single dose of cyclosporine ( 30 mg ) or tacrolimus ( 2 mg ) in healthy volunteers ( N = 12 per study ) .
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ABT-450, ombitasvir, and dasabuvir are direct-acting antiviral agents (DAAs) that have been developed for combination treatment of chronic hepatitis C virus (HCV) infection. Because these DAAs have metabolic and transporter profiles that overlap with cyclosporine and tacrolimus disposition, there is potential for drug interactions. Two Phase 1 studies assessed effects of ABT-450 ( 150 mg coadministered with ritonavir 100 mg once daily ) , ombitasvir ( 25 mg once daily ) , and dasabuvir ( 400 mg twice daily ) on the pharmacokinetics , safety , and tolerability of a single dose of cyclosporine ( 30 mg ) or tacrolimus ( 2 mg ) in healthy volunteers ( N = 12 per study ) . In the presence of steady-state concentrations of all 3 DAAs, dose-normalized cyclosporine concentration at 24 hours (C₂₄), and area under the concentration-time curve from time 0 to infinity (AUC(∞)) were 15.8-fold and 5.8-fold, respectively, and dose-normalized tacrolimus C₂₄ and AUC(∞) were 17-fold and 57-fold, respectively, of either agent alone. cyclosporine and tacrolimus half-lives increased from 7 to 25 h and 32 to 232 h, respectively. There were no major safety or tolerability issues in these studies. The results suggest that cyclosporine and tacrolimus doses and dosing frequency should be reduced in HCV-infected posttransplant patients being treated with this 3-DAA regimen.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ABT-450, ombitasvir, and dasabuvir are direct-acting antiviral agents (DAAs) that have been developed for combination treatment of chronic hepatitis C virus (HCV) infection. Because these DAAs have metabolic and transporter profiles that overlap with cyclosporine and tacrolimus disposition, there is potential for drug interactions. Two Phase 1 studies assessed effects of ABT-450 ( 150 mg coadministered with ritonavir 100 mg once daily ) , ombitasvir ( 25 mg once daily ) , and dasabuvir ( 400 mg twice daily ) on the pharmacokinetics , safety , and tolerability of a single dose of cyclosporine ( 30 mg ) or tacrolimus ( 2 mg ) in healthy volunteers ( N = 12 per study ) . In the presence of steady-state concentrations of all 3 DAAs, dose-normalized cyclosporine concentration at 24 hours (C₂₄), and area under the concentration-time curve from time 0 to infinity (AUC(∞)) were 15.8-fold and 5.8-fold, respectively, and dose-normalized tacrolimus C₂₄ and AUC(∞) were 17-fold and 57-fold, respectively, of either agent alone. cyclosporine and tacrolimus half-lives increased from 7 to 25 h and 32 to 232 h, respectively. There were no major safety or tolerability issues in these studies. The results suggest that cyclosporine and tacrolimus doses and dosing frequency should be reduced in HCV-infected posttransplant patients being treated with this 3-DAA regimen.

            ### Response:
            ABT-450, ritonavir, ombitasvir, dasabuvir, cyclosporine, tacrolimus
            